Business Description
Pasithea Therapeutics is a clinical-stage company founded in 2020 and based in Miami Beach, Florida, that is working to develop new treatments for brain and nervous system conditions, certain genetic disorders, and cancer. Its most advanced drug candidate, PAS-004, is designed to target a specific biological pathway involved in conditions such as neurofibromatosis type 1, certain tumor types, and inflammatory diseases including bowel disease and joint conditions. The company is also developing PAS-003 for ALS and plans to advance PAS-001 as a potential treatment for schizophrenia.
